Form 4: LENZ Therapeutics Director Jeffrey P. George Granted 13,500 Stock Options

Jeffrey P. George, a Director at LENZ Therapeutics, Inc., was granted 13,500 stock options with an exercise price of $30, vesting fully on June 11, 2026.

Summary

• Jeffrey P. George, a Director of LENZ Therapeutics, Inc. (LENZ), was granted 13,500 stock options.
• The transaction date for this grant was June 11, 2025.
• The exercise price for these stock options is $30 per share.
• The options will fully vest on June 11, 2026, provided Mr. George continues to serve as an Outside Director.
• The expiration date for these options is June 10, 2035.
• Following this transaction, Mr. George beneficially owns 13,500 derivative securities (stock options) directly.
• A Power of Attorney was executed on June 11, 2025, by Jeffrey P. George, authorizing specific individuals to file SEC reports on his behalf.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it represents a standard equity grant to a director, aligning their interests with shareholders. It does not contain any negative news or significant positive operational updates.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, as the options gain value if the company's stock price increases above the exercise price.
• The vesting schedule encourages long-term commitment from the director to the company's performance.

Negatives

• No specific negative financial or operational information is disclosed in this Form 4 filing.

Risks

• The value of the stock options is subject to the future performance of LENZ Therapeutics' common stock; if the stock price does not exceed the $30 exercise price, the options may expire worthless.

Future Outlook

This document does not provide a future outlook for the company's financial performance or strategic direction, focusing solely on an individual's equity transaction.

Industry Context

This Form 4 filing is a standard disclosure of an insider equity transaction, common across all industries for publicly traded companies. It does not provide specific industry-wide trends or competitive analysis.

Corporate Governance

Related Party Transactions

• The grant of stock options to Jeffrey P. George, a Director of LENZ Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a mechanism to align management incentives with shareholder value creation, as the options' value increases with the stock price.
• Employees: This filing does not directly impact general employees, but it reflects standard executive compensation practices.

Next Steps

• The stock options are scheduled to vest on June 11, 2026, contingent on Jeffrey P. George's continued service as an Outside Director.

Key Dates

Keywords

LENZ Therapeutics, LENZ, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Jeffrey P. George